Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract
Phase 2
- Conditions
- Nuclear Cataract
- Interventions
- Drug: C-KAD Ophthalmic SolutionDrug: LiquiTears
- Registration Number
- NCT00825721
- Lead Sponsor
- Chakshu Research, Inc.
- Brief Summary
This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 81
Inclusion Criteria
- Presence of nuclear sclerosis cataract
- BCDVA within the range of 20/40 and 20/80
Exclusion Criteria
- Any other clinical condition in the eye that may compromise vision
- Presence or history of glaucoma
- Presence or history of diabetes
- Use of eyedrops
- Use of steroids
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1.3% (low dose) C-KAD Ophthalmic Solution - 2% (medium dose) C-KAD Ophthalmic Solution - 2.6% (high dose) C-KAD Ophthalmic Solution - Placebo LiquiTears -
- Primary Outcome Measures
Name Time Method Best-corrected visual acuity by ETDRS 360 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does C-KAD Ophthalmic Solution target in age-related nuclear cataract progression?
How does C-KAD Ophthalmic Solution compare to standard-of-care treatments for nuclear cataract in terms of efficacy and safety?
Which biomarkers are associated with response prediction to C-KAD Ophthalmic Solution in patients with nuclear cataract?
What are the potential adverse events and management strategies for C-KAD Ophthalmic Solution in phase 2 trials for nuclear cataract?
Are there combination approaches or competitor drugs for age-related nuclear cataract treatment alongside C-KAD Ophthalmic Solution?
Trial Locations
- Locations (1)
Tilganga Eye Center
🇳🇵Kathmandu, Nepal
Tilganga Eye Center🇳🇵Kathmandu, Nepal